Sign in Subscribe
Cancer research

New Insights into Interstitial Lung Disease Treatment

Strategic Insights

— 1 min read

New research conducted by a team of experts at the Shinshu University School of Medicine has shed light on the treatment of Interstitial Lung Disease (ILD), a condition that can be caused by lung cancer. The study, published in the Respiratory Investigation journal, analyzed data from 181 patients with extensive-disease small cell lung cancer (ED-SCLC) who received first-line chemotherapy or chemoimmunotherapy between August 2019 and June 2023. The findings suggest that, despite the effectiveness of chemoimmunotherapy in clinical trials, only about half of the patients with ED-SCLC select this treatment option, highlighting various challenges in the treatment of ED-SCLC in clinical settings.

Key Takeaways:

  • Ninety-six (53.0 %) and 85 (47.0 %) ED-SCLC patients received chemoimmunotherapy and chemotherapy, respectively.
  • The proportions of older patients (75 years) and those with interstitial pneumonia were significantly higher in the chemotherapy group than in the chemoimmunotherapy group (age: 56.5 % vs. 28.1 %, p<0.01, respectively).
  • The study found that, despite the introduction of chemoimmunotherapy, there are still various challenges in the treatment of ED-SCLC in clinical settings.
  • The research suggests that a multicenter retrospective study is necessary to investigate the characteristics and treatment regimens of patients with ED-SCLC who received first-line treatment.
  • The study's authors, including Taro Hirabayashi, First Dept. of Internal Medicine, Shinshu University School of Medicine, and Kei Sonehara, emphasize the importance of understanding the real-world treatment outcomes for patients with ED-SCLC.
  • The study was peer-reviewed and published in the Respiratory Investigation journal.

Statistics:

  • 18.5% of ED-SCLC patients receiving chemoimmunotherapy were older than 75 years.
  • 25.8% of ED-SCLC patients receiving chemotherapy had interstitial pneumonia.
  • 53.0% of ED-SCLC patients received chemoimmunotherapy.
  • 47.0% of ED-SCLC patients received chemotherapy.

Sources:

  • Real-world data after introduction of chemoimmunotherapy in patients with extensive-disease small cell lung cancer: A multicenter retrospective study. Respiratory Investigation, 2025;63(5):928-933. (Elsevier - www.elsevier.com; Respiratory Investigation - www.journals.elsevier.com/respiratory-investigation/)
  • NewsRx. New Interstitial Lung Disease Findings from Shinshu University School of Medicine Reported (Real-world data after introduction of chemoimmunotherapy in patients with extensive-disease small cell lung cancer: A multicenter retrospective study). Immunotherapy Weekly. August 13, 2025; p 1529.

Read more